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Down's syndrome (DS) is a genetic disorder caused by full or partial trisomy of human chromosome 21 and presents with many clinical phenotypes including a reduced incidence of solid tumours 1, 2 . Recent work with the Ts65Dn model of DS, which has orthologues of about 50% of the genes on chromosome 21 (Hsa21), has indicated that three copies of the ETS2 (ref.
3) or DS candidate region 1 (DSCR1) genes 4 (a previously known suppressor of angiogenesis 5, 6 ) is sufficient to inhibit tumour growth. Here we use the Tc1 transchromosomic mouse model of DS 7 to dissect the contribution of extra copies of genes on Hsa21 to tumour angiogenesis. This mouse expresses roughly 81% of Hsa21 genes but not the human DSCR1 region. We transplanted B16F0 and Lewis lung carcinoma tumour cells into Tc1 mice and showed that growth of these tumours was substantially reduced compared with wild-type littermate controls. Furthermore, tumour angiogenesis was significantly repressed in Tc1 mice. In particular, in vitro and in vivo angiogenic responses to vascular endothelial growth factor (VEGF) were inhibited. Examination of the genes on the segment of Hsa21 in Tc1 mice identified putative anti-angiogenic genes (ADAMTS1 8, 9 and ERG
10
) and novel endothelial cell-specific genes 11 , never previously shown to be involved in angiogenesis (JAM-B 12 and PTTG1IP), that, when overexpressed, are responsible for inhibiting angiogenic responses to VEGF. Three copies of these genes within the stromal compartment reduced tumour angiogenesis, explaining the reduced tumour growth in DS. Furthermore, we expect that, in addition to the candidate genes that we show to be involved in the repression of angiogenesis, the Tc1 mouse model of DS will permit the identification of other endothelium-specific anti-angiogenic targets relevant to a broad spectrum of cancer patients.
DS, or trisomy 21, is responsible for developmental abnormalities, learning disability, cardiovascular defects and dementia 1 . As well as these phenotypes, which have been well documented in DS, three independent studies have drawn attention to the fact that malignant solid tumours are under-represented when compared with agematched and sex-matched individuals from the general population 1,2 . This phenotype is probably due to 'gene dosage' effects; that is, an extra copy of Hsa21 leads to higher levels of gene product protecting DS individuals from solid tumour growth. Orthology to Hsa21 is found on three mouse chromosomes: Mmu16, Mmu17 and Mmu10, with 29 genes found on Hsa21 not being represented in the mouse ( Supplementary Fig. 1 ). Early transgenic mouse models, including the Ts65Dn model, which contains orthologues of up to only 50% of the genes located on Hsa21, have been used to study the reduced solid tumour malignancies 3 . However, it was not possible to examine the contribution of trisomy 21 specifically to angiogenesis, a process essential for solid tumour growth, in this system because all cells, including the tumour cells and stromal cells, were potentially trisomic. We used the Tc1 mouse model of DS 7 , which has 81% of Hsa21 genes but lacks the duplication of 29 genes including DSCR1, to test the effect of this additional segment of chromosome 21 specifically on tumour neovascularization (Supplementary Fig. 1 ).
To determine whether Tc1 mice were protected from solid tumour growth, we examined the growth of B16F0 and Lewis lung carcinoma (LLC) tumour xenografts. Tumour growth of both B16F0 and LLC was significantly repressed in Tc1 mice in comparison with wild-type controls (Fig. 1a) . Additionally, LLC tumour growth kinetics were significantly slower in Tc1 mice, especially at larger tumour sizes, which require neovascularization rather than vessel co-option 13 (Supplementary Fig. 2 ). To confirm that this phenotype was not the result of a disproportionate increase of Mmu10, Mmu16 and Mmu17 relative to the ploidy of the tumour cells, we examined the chromosomes in the B16F0 and LLC cell lines. Mmu10, Mmu16 and Mmu17 were found to be correct relative to the ploidy ( Supplementary Fig. 3 ). These observations confirm that three copies of chromosome 21 genes suppress the growth of tumours through reduced tumour neoangiogenesis.
To address specifically the contribution of tumour angiogenesis to this phenotype, we examined the tumour vasculature. The additional Hsa21 fragment in Tc1 mice induced a significant and substantial decrease in tumour blood vessel density in both B16F0 and LLC tumours in comparison with tumours grown in wild-type littermate controls (Fig. 1b) . Dextran-fluorescein isothiocyanate (FITC)-perfused blood vessel numbers were also decreased in Tc1 mouse tumours (Fig. 1c) . In contrast, examination of blood vessel density in unchallenged skin and other organs from wild-type control and Tc1 mice showed no difference between the genotypes (Fig. 1d and Supplementary Fig. 4 ), suggesting that pathological angiogenesis, but not normal blood vessel density, is negatively affected by the Hsa21 fragment. In addition, the growth of Tc1 endothelial cells was not affected by the additional Hsa21 fragment 14 ( Supplementary Fig. 5 ). Furthermore, the differences in tumour vascularity were not due to differences in immune-cell infiltration between the genotypes ( Supplementary  Fig. 6 ), and the contribution of Tc1 bone-marrow-derived cells to tumour growth was not apparent (Supplementary Fig. 7 ). Taken together, our data from Tc1 mice suggest that it is the presence of an additional copy of a fragment of Hsa21, within blood vessels, that inhibits solid tumour growth and represses tumour angiogenesis.
To assess whether the decreased tumour angiogenesis observed in the Tc1 mice was due to reduced sensitivity to VEGF, we performed in vivo growth-factor-induced angiogenesis assays. VEGF-mediated neovascularization was reduced significantly in the Tc1 mice in comparison with littermate controls (Fig. 2a) . Treatment with PBS resulted in similar baseline angiogenic responses in both genotypes (data not shown). In addition to the lack of in vivo angiogenesis, Tc1 aortic rings were also unresponsive to stimulation with VEGF, in contrast to VEGF-treated wild-type controls. Baseline responses to PBS were not affected in the Tc1 aortic rings, indicating further that an additional copy of the fragment of Hsa21 specifically suppresses VEGF-induced neovascularization (Fig. 2b) .
Vascular endothelial growth factor receptor 2 (VEGFR2) is a major pro-angiogenic growth factor receptor 15 . VEGF, by means of VEGFR2, induces extracellular signal-regulated kinase (ERK)1/2 (p42/p44) phosphorylation and mediates endothelial cell activation during angiogenesis, and inhibition of VEGFR2 or the ERK1/2 pathway reduces VEGF-mediated angiogenic responses 16 . ERK1/2 phosphorylation was reduced specifically in response to VEGF, but not basic fibroblast growth factor (bFGF), in Tc1 endothelial cells in comparison with wild-type controls and in VEGF-stimulated primary cells isolated from individuals with DS ( Fig. 2c, d , and Supplementary Fig. 8 ). This specific response to VEGF focused our attention on VEGFR2.
Although other molecules, such as DYRK1A (dual-specificity tyrosine-phosphorylation-regulated kinase 1A), have been reported to be upstream of ERK signalling 17 and may contribute to the decreased ERK phosphorylation in response to VEGF, we show that surface levels, but not total levels, of VEGFR2 are substantially increased in Tc1 endothelial cells ( Supplementary Fig. 9a , b). After stimulation with VEGF, the surface levels of VEGFR2 remain consistently higher on Tc1 endothelial cells than on control cells ( Supplementary Fig. 9c ). This discrepancy between total VEGFR2 and surface VEGFR2 levels indicates that Tc1 endothelial cells have lower cytoplasmic levels of VEGFR2. Indeed, examination of endothelial cells in culture by immunofluorescence show that stimulation of wild-type cells with VEGF induced an apparent internalization of phosphorylated VEGFR2 that was not present in Tc1 endothelial cells (Supplementary Fig. 9c ). The phosphorylated VEGFR2 in Tc1 endothelial cells seemed to be restricted at the cell surface after stimulation with VEGF. Although beyond the scope of the study, it is tempting to speculate that defects in VEGFR2 subcellular localization are relevant to the repressed angiogenesis in Tc1 mice and provide a novel aspect to the regulation of angiogenesis in DS 18, 19 . We identified several putative anti-tumorigenic, anti-angiogenic and endothelial-cell-specific genes expressed on Hsa21 in the Tc1 mice likely to be responsible for the decreased angiogenic responses. These included ETS2, encoding a transcription factor whose overexpression reduces tumour growth in the Ts65Dn mouse model of DS and in other models 3,20 but is not yet linked with angiogenesis; ADAMTS1, encoding a protease known to inhibit angiogenesis 8,9,21 ; and three endothelial-cell-specific Hsa21 genes (ERG, encoding a transcription factor implicated in endothelial tube formation and angiogenesis 10 ; JAM-B, encoding a cell-cell adhesion molecule not yet implicated in angiogenesis or tumorigenesis; and PTTG1IP, which is overexpressed in cancers but is also not yet linked to angiogenesis). All mouse transcripts were expressed in Tc1 and wild-type endothelial cells and human transcripts only in the Tc1 endothelial cells ( Supplementary Fig. 10a, b) . To test whether three copies of any of these candidate genes negatively affected angiogenesis, we first observed the effects of depleting individual human transcripts by RNA-mediated interference (RNAi) on VEGF-mediated microvessel sprouting in aortic ring assays (Fig. 3) . Knockdown of the human transcripts and protein in Tc1 endothelial cells was confirmed by RT-PCR and western blot analysis, and no detectable effects on mouse orthologues were observed ( Fig. 3a and Supplementary Fig. 11 ). Wild-type aortic rings stimulated with VEGF showed a significant increase in microvessel sprouting that was not affected by treatment with scrambled (Scr) short interfering RNA (siRNA) or the humanspecific siRNAs against ETS2, ERG, ADAMTS1, JAM-B or PTTG1IP (Fig. 3b) . This was expected, because these aortic rings lacked any human genes and acted as a control. In contrast, Tc1 aortic rings did not show enhanced microvessel sprouting in response to stimulation with VEGF with or without Scr-siRNA transfection (Fig. 3c) . However, the use of human-specific siRNAs to deplete one of three copies of ERG, ADAMTS1, JAM-B or PTTG1IP transcripts (effectively recreating wild-type copy numbers for each gene) was sufficient to restore VEGF-mediated microvessel sprouting to VEGF-treated wildtype levels. Depletion of one of three copies of ETS2 did not induce a significant increase in microvessel sprouting in response to VEGF (Fig. 3c) , suggesting that vascular ETS2 is not involved in this response. In contrast, data from ref. 3 suggest that ETS2 is involved in the growth of spontaneous intestinal tumours in APC min mice. Taken together, these data suggest that the effect of ETS2 occurs in the non-stromal tumour cell compartment. Indeed, ETS2 has been reported to be responsible for different biological responses in different cell types [22] [23] [24] . Our data provide an example of how the xenograft model used in the Tc1 mice enables us to dissect the role of genes in the tumour and in the stromal compartment.
To test the gene-dosage effect of the remaining candidate genes further, we used mouse-specific siRNAs to deplete two of three transcript copies in Tc1 aortic rings. Using RT-PCR we showed that mouse-specific siRNAs for the candidate genes Erg, Adamts1, Jam-b and Pttg1ip effectively depleted mouse transcripts in Tc1 endothelial cells (Fig. 4a) . As in Fig. 3c , VEGF treatment of Tc1 aortic rings that were either untransfected or transfected with Scr-siRNA did not induce an increase in microvessel sprouting over untreated control aortic rings. In contrast, targeting the mouse Adamts1, Jam-b or Pttg1ip transcripts by siRNA promoted VEGF-mediated microvessel sprouting over and above Scr-siRNA-treated controls. Depleting two of three copies of these transcripts (effectively reducing the copy number of each gene from three to one) is sufficient to promote VEGF-mediated microvessel sprouting (Fig. 4b) . Taken together, our data show that for Adamts1, Jam-b and Pttg1ip one or two copies of the transcript is sufficient to restore normal levels of VEGF-mediated vessel sprouting, suggesting that a gene dosage effect is mediating the repressed angiogenic phenotype in the Tc1 mice. In contrast, depleting two of three copies of the Erg gene did not affect VEGF-mediated vessel sprouting, suggesting that two copies of this transcript are required for normal angiogenic responses.
In addition, an antibody against mouse JAM-B was injected into B16F0-tumour-burdened Tc1 mice. Intraperitoneal administration of this antibody increased tumour size and blood vessel density significantly in Tc1 mice in comparison with control-IgG-injected Tc1 controls (Fig. 4c) . To provide direct evidence of a gene-dosage effect of JAM-B on angiogenesis we compared angiogenesis in wild-type mice (two copies of JAM-B) with that in JAM-B heterozygous mice (one copy of JAM-B). JAM-B heterozygous mouse tissue showed roughly half the levels of JAM-B (Supplementary Fig. 12 ). B16F0 tumour size and blood vessel density were increased significantly in JAM-B heterozygous mice in comparison with wild-type mice (Fig. 4d, e) . Furthermore, aortic rings from JAM-B heterozygous mice showed a significant increase in VEGF-mediated aortic vessel sprouting (Fig. 4f) . Finally, we compared VEGF-induced angiogenesis ex vivo by using aortae isolated from wild-type and ADAMTS1 heterozygous mice. Once again, our data showed a gene-dosage effect of ADAMTS1 on angiogenesis and corroborate previous findings in which genetic ablation of ADAMTS1 enhanced angiogenesis 25 ( Supplementary  Fig. 13 ). Taken together, these results confirm that one extra copy of the candidate genes on Hsa21 can provide an anti-angiogenic effect.
Our work establishes that three copies of individual genes in the stromal compartment can confer a repressed tumour angiogenic phenotype in the Tc1 mouse model of DS, supporting the notion of a 'gene-dosage' effect, for some genes, protecting DS individuals can rescue the angiogenic defect in Tc1 mice. a, siRNA depletion of the candidate human genes inhibited human (Hu) transcript expression levels (left panel) but not mouse transcript expression levels (right panel). b, Knockdown of human candidate genes in wild-type aortic tissue has no effect. Non-transfected (NT) wild-type (WT) aortic rings treated with VEGF (1) enhanced microvessel sprouting compared with untreated aortic rings (2). Scr-siRNA or human-specific siRNAs did not alter VEGF-mediated microvessel sprouting. c, Knockdown of human candidate genes in Tc1 aortic tissue restores disomy. Non-transfected (NT) and Scr-siRNAtransfected Tc1 aortic rings did not respond to VEGF (1). Transfection with human-specific siRNAs, except ETS2, effectively restoring expression of two copies of the genes, increased VEGF-mediated vessel sprouting. LETTERS from solid tumour growth 1,2 . In particular, VEGF-mediated angiogenic processes are inhibited by the addition of a fragment of Hsa21 in the Tc1 mice. Our data show that individual depletion of JAM-B, ADAMTS1, ERG or PTTG1IP, but not ETS2, is sufficient to restore normal angiogenic responses to VEGF. This implies that three copies of JAM-B, ADAMTS1, ERG and PTTG1IP, and probably others that we have not tested, need to be present for the overall inhibitory effect. The transchromosomic system used in our study has a unique advantage in allowing species-specific silencing of the third gene copy, leading to a rapid genetic dissection and pinpointing of the causative trisomic genes. Although beyond the scope of the present study, our results imply that JAM-B, ADAMTS1, ERG and PTTG1IP, but not ETS2, are upstream of a common signalling pathway in the control of angiogenic responses.
Although we see a phenotype in Tc1 mice similar to that described in ref. 4, the mechanisms of this regulation are likely to be different because the DSCR1 region is triplicated in TS65Dn mice but expressed at normal levels in Tc1 mice. Because of this, changes in DSCR1-mediated signalling through calcineurin are unlikely to be affected in Tc1 mice. Indeed, although the overexpression of DSCR1 has been shown to inhibit tumour angiogenesis, overexpression of this gene is also thought to contribute to several pathological defects 26 , suggesting that manipulation of DSCR1 downstream signalling may have limited anti-angiogenic therapeutic potential. In contrast, our studies not only confirmed the function of known antiangiogenic genes on Hsa21 but also identified and tested novel endothelium-specific genes that are anti-angiogenic when overexpressed. Our data highlight the importance of ADAMTS1, JAM-B, PTTG1IP and other, potentially novel, genes in controlling tumour angiogenesis. Furthermore, we have identified JAM-B and PTTG1IP as new antiangiogenic mediators.
Our study reveals that repression of angiogenesis by the addition of a fragment of Hsa21 in DS models can direct the discovery of new anti-angiogenic targets, which have the potential of being exploited pharmacologically for the development of effective gene therapy for treating cancer.
METHODS SUMMARY
Mice. Tc(Hsa21)1TybEmcf (Tc1) mice were generated by crossing Tc1 females with (129S8 3 B6)F 1 males 7 . In vivo tumour assays. In vivo tumour assays and tumour kinetic studies were performed as described previously 27, 28 . The anti-JAM-B antibody (clone JB4.2) was developed in B. A. Imhof's laboratory and will be described elsewhere. For JAM-B blocking experiments, 100 mg of JB4.2 was injected intraperitoneally every 3 days into tumour-burdened Tc1 and wild-type mice. On day 12, tumours were measured and processed for histological analysis. Subcutaneous angiogenesis assay. Assays were performed as described previously 29 . On day 14 the sponges were harvested and fixed for immunostaining for blood vessel examination. Western blot analysis. Wild-type and Tc1 primary endothelial cells were lysed, and 30-100 mg of protein for each protein sample was loaded onto 8-12% gels and western blot analysis was performed (VEGFR2/phospho-VEGFR2, ERK1/2 and phospho-ERK1/2 were from Cell Signaling Technology). Anti-ADAMTS1 antibody was a gift from L. Iruela-Arispe. Anti-PTTG1IP antibody was raised in rabbits against the human PTTG1IP protein. Anti-JAM-B antibody was provided by B. A. Imhof. Aortic ring assay. This assay was performed as described previously 28 . For RNAi studies, aortic rings were transfected with various siRNAs (Dharmacon) before being embedded in collagen. Blood vessel quantification. Sections of size-matched tumours or sponges were immunostained with rat anti-endomucin (Santa Cruz) antibody to identify blood vessels. The number of blood vessels was counted as described previously 28 . Statistical analysis. Statistical significance was calculated with Student's t-test. P , 0.05 was considered statistically significant. Animal regulations. All animals were used in accordance with UK Home Office regulations.
Full Methods and any associated references are available in the online version of the paper at www.nature.com/nature. candidate genes inhibited mouse endothelial transcript expression levels. b, Knockdown of mouse candidate genes in Tc1 aortic tissue induces monosomy. Non-transfected (NT) and Scr-siRNA-transfected Tc1 aortic rings did not sprout in response to VEGF (1). Transfection with Adamts1, Jam-b and Pttg1ip siRNA, effectively generating one copy of the genes, increased VEGF-mediated vessel sprouting. Transfection with Erg siRNA had no effect on VEGF-mediated microvessel sprouting. n 5 20-40 aortic rings per test. c, Administration of the anti-mouse JAM-B antibody (JB4.2) to tumour-burdened Tc1 mice enhanced tumour growth and blood vessel density. Asterisk, P , 0.005; two asterisks, P , 0.001; n.s., not statistically significant. d, Tumour volume was increased in JAM-B 1/2 mice. Asterisk, P , 0.05. e, Tumour blood vessel density was increased in JAM-B 1/2 mice. Asterisk, P , 0.05. f, VEGF-mediated microvessel sprouting was increased in JAM-B 1/2 aortic rings. n 5 24-68 aortic rings per genotype per test. Scale bars, 100 mm. Asterisk, P , 0.05; two asterisks, P , 0.005. All values are means and s.e.m.
